Use of miR-494 to modulate TRAIL-induced apoptosis through BIM down-regulation
AssigneeOhio State Innovation Foundation
InventorsCarlo M. Croce, Giulia Romano
Life of this patent
Estimating the term…
Loading patent…
AssigneeOhio State Innovation Foundation
InventorsCarlo M. Croce, Giulia Romano
Estimating the term…
Methods and compositions for inhibiting tumorigenicity both in vitro and in vivo in a subject in need thereof, comprising administering an effective amount of an anti-miR-494 nucleic acid construct sufficient to target one or more tumor suppressor genes (TSGs) are described. Activation of the ERK1/2 pathway is a major determinant of diverse cellular processes and cancer development and is responsible for the transcription of several important miRNAs. Described herein is a link between the ERK1/2 pathway and BIM expression through miR-494. This ERK1/2 pathway regulates apoptosis and cell proliferation through miR-494 and mechanisms responsible for TRAIL resistance. Materials and methods related to the study and treatment of cancer are described.
A method to inhibit down-regulation of Bcl-2-like protein 11 (BIM) in a TRAIL-resistant cancer cell that over-expresses miR-494, comprising administering an effective amount of at least one inhibitor of miR-494 to the cancer cell and inhibiting BIM down-regulation.
Dependencies are inferred from the claim text.